A general strategy to construct small molecule biosensors in eukaryotes

  1. Justin Feng
  2. Benjamin W Jester
  3. Christine E Tinberg
  4. Daniel J Mandell  Is a corresponding author
  5. Mauricio S Antunes
  6. Raj Chari
  7. Kevin J Morey
  8. Xavier Rios
  9. June I Medford
  10. George M Church
  11. Stanley Fields
  12. David Baker
  1. Harvard Medical School, United States
  2. University of Washington, United States
  3. Colorado State University, United States
  4. Howard Hughes Medical Institute, University of Washington, United States

Abstract

Biosensors for small molecules can be used in applications that range from metabolic engineering to orthogonal control of transcription. Here, we produce biosensors based on a ligand-binding domain (LBD) by using a method that, in principle, can be applied to any target molecule. The LBD is fused to either a fluorescent protein or a transcriptional activator and is destabilized by mutation such that the fusion accumulates only in cells containing the target ligand. We illustrate the power of this method by developing biosensors for digoxin and progesterone. Addition of ligand to yeast, mammalian or plant cells expressing a biosensor activates transcription with a dynamic range of up to ~100-fold. We use the biosensors to improve the biotransformation of pregnenolone to progesterone in yeast and to regulate CRISPR activity in mammalian cells. This work provides a general methodology to develop biosensors for a broad range of molecules in eukaryotes.

Article and author information

Author details

  1. Justin Feng

    Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, United States
    Competing interests
    Harvard University has filed a provisional patent on this work
  2. Benjamin W Jester

    Department of Genome Sciences, University of Washington, Seattle, United States
    Competing interests
    Harvard University has filed a provisional patent on this work
  3. Christine E Tinberg

    Department of Biochemistry, University of Washington, Seattle, United States
    Competing interests
    Harvard University has filed a provisional patent on this work
  4. Daniel J Mandell

    Department of Genetics, Harvard Medical School, Boston, United States
    For correspondence
    djmandell@gmail.com
    Competing interests
    Harvard University has filed a provisional patent on this work
  5. Mauricio S Antunes

    Department of Biology, Colorado State University, Fort Collins, United States
    Competing interests
    No competing interests declared.
  6. Raj Chari

    Department of Genetics, Harvard Medical School, Boston, United States
    Competing interests
    Harvard University has filed a provisional patent on this work
  7. Kevin J Morey

    Department of Biology, Colorado State University, Fort Collins, United States
    Competing interests
    No competing interests declared.
  8. Xavier Rios

    Department of Genetics, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  9. June I Medford

    Department of Biology, Colorado State University, Fort Collins, United States
    Competing interests
    No competing interests declared.
  10. George M Church

    Department of Genetics, Harvard Medical School, Boston, United States
    Competing interests
    Harvard University has filed a provisional patent on this work
  11. Stanley Fields

    Department of Genome Sciences, University of Washington, Seattle, United States
    Competing interests
    Harvard University has filed a provisional patent on this work
  12. David Baker

    Howard Hughes Medical Institute, University of Washington, Seattle, United States
    Competing interests
    Harvard University has filed a provisional patent on this work

Reviewing Editor

  1. Jeffery W Kelly, Scripps Research Institute, United States

Publication history

  1. Received: August 6, 2015
  2. Accepted: December 17, 2015
  3. Accepted Manuscript published: December 29, 2015 (version 1)
  4. Accepted Manuscript updated: December 30, 2015 (version 2)
  5. Version of Record published: January 26, 2016 (version 3)

Copyright

© 2015, Feng et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 12,914
    Page views
  • 3,103
    Downloads
  • 113
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Justin Feng
  2. Benjamin W Jester
  3. Christine E Tinberg
  4. Daniel J Mandell
  5. Mauricio S Antunes
  6. Raj Chari
  7. Kevin J Morey
  8. Xavier Rios
  9. June I Medford
  10. George M Church
  11. Stanley Fields
  12. David Baker
(2015)
A general strategy to construct small molecule biosensors in eukaryotes
eLife 4:e10606.
https://doi.org/10.7554/eLife.10606

Further reading

    1. Biochemistry and Chemical Biology
    2. Cancer Biology
    Madeleine L Hart, Evan Quon ... Lucas B Sullivan
    Research Article Updated

    The oxidative tricarboxylic acid (TCA) cycle is a central mitochondrial pathway integrating catabolic conversions of NAD +to NADH and anabolic production of aspartate, a key amino acid for cell proliferation. Several TCA cycle components are implicated in tumorigenesis, including loss-of-function mutations in subunits of succinate dehydrogenase (SDH), also known as complex II of the electron transport chain (ETC), but mechanistic understanding of how proliferating cells tolerate the metabolic defects of SDH loss is still lacking. Here, we identify that SDH supports human cell proliferation through aspartate synthesis but, unlike other ETC impairments, the effects of SDH inhibition are not ameliorated by electron acceptor supplementation. Interestingly, we find aspartate production and cell proliferation are restored to SDH-impaired cells by concomitant inhibition of ETC complex I (CI). We determine that the benefits of CI inhibition in this context depend on decreasing mitochondrial NAD+/NADH, which drives SDH-independent aspartate production through pyruvate carboxylation and reductive carboxylation of glutamine. We also find that genetic loss or restoration of SDH selects for cells with concordant CI activity, establishing distinct modalities of mitochondrial metabolism for maintaining aspartate synthesis. These data therefore identify a metabolically beneficial mechanism for CI loss in proliferating cells and reveal how compartmentalized redox changes can impact cellular fitness.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Sean M Braet, Theresa SC Buckley ... Ganesh Srinivasan Anand
    Research Article

    SARS-CoV-2 emergent variants are characterized by increased viral fitness and each shows multiple mutations predominantly localized to the spike (S) protein. Here, amide hydrogen/deuterium exchange mass spectrometry has been applied to track changes in S dynamics from multiple SARS-CoV-2 variants. Our results highlight large differences across variants at two loci with impacts on S dynamics and stability. A significant enhancement in stabilization first occurred with the emergence of D614G S followed by smaller, progressive stabilization in subsequent variants. Stabilization preceded altered dynamics in the N-terminal domain, wherein Omicron BA.1 S showed the largest magnitude increases relative to other preceding variants. Changes in stabilization and dynamics resulting from S mutations detail the evolutionary trajectory of S in emerging variants. These carry major implications for SARS-CoV-2 viral fitness and offer new insights into variant-specific therapeutic development.